Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients
Status:
Terminated
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label study of 2 doses of leuprolide acetate 17 mg depot,
administered three months apart, in subjects with prostate cancer who might benefit from
medical androgen deprivation therapy